Co-Diagnostics

Rank#10993

Market Cap7.61M

CountryUnited States

Summary

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

History

Co-Diagnostics was founded in April 2014, as a Utah-based molecular diagnostics company. The company designs, develops, and manufactures in vitro diagnostic (IVD) tests intended for use in developing countries. Co-Diagnostics specializes in the development of syndromic multiplex PCR-based molecular diagnostics testing.

Mission

Our mission is to provide innovative, affordable, and easy-to-use diagnostic products to medical professionals around the world.

Vision

Our vision is to create a world of improved healthcare and quality of life through the use of our innovative diagnostic products.

References

https://en.wikipedia.org/wiki/Coordinated_diagnostics

https://in.investing.com/equities/co-diagnostics

https://finance.yahoo.com/quote/CODX/profile?p=CODX

https://www.crunchbase.com/organization/co-diagnostics

https://companiesmarketcap.com/

https://www.codiagnostics.com

Leadership team